GLP-1 Medications and Psoriasis: What the Research Shows

Introduction

For most of the last decade, a dermatologist who noticed their psoriasis patient had lost 20 kg on semaglutide would have called the clearer skin a pleasant side effect. In April 2026, that changed. The National Psoriasis Foundation Medical Board published a primer in JAMA Dermatology endorsing consideration of GLP-1 medications as an adjunctive treatment in patients with psoriasis and metabolic comorbidities — the first time a major dermatology body has positioned these drugs as something closer to therapy than coincidence.

The link between psoriasis and metabolic disease is not new. Psoriasis travels with obesity, type 2 diabetes, fatty liver, and cardiovascular disease at rates far above the general population, and the relationship runs both directions: excess adipose tissue is an active endocrine organ that pumps out IL-17, IL-6, and TNF-α, the same cytokines that drive psoriatic plaques.

Evidence: "GLP-1 RAs may reduce psoriasis severity among patients with metabolic comorbidities, though larger randomized clinical trials are needed to further guide appropriate use of GLP-1 RAs among patients with psoriasis." — Sheth S, Merola JF, Weber BN, et al. JAMA Dermatology. 2026. DOI: 10.1001/jamadermatol.2026.0859

What follows is the evidence behind that endorsement — how strong it actually is, which patients it applies to, and the unresolved question of whether these drugs treat psoriasis or simply treat the obesity that inflames it.

Why GLP-1 Medications Might Help Psoriasis

Two mechanisms are on the table, and they are not mutually exclusive.

The first is straightforward weight loss. Adipose tissue is inflammatory. Shrink it, and systemic cytokine load falls. This mechanism is well established independently of GLP-1 drugs — a 2025 meta-analysis of 13 randomized trials covering 1,145 participants found that weight-loss interventions of any kind, mostly diet and exercise, meaningfully improved psoriasis severity.

Evidence: "Weight-loss interventions produced a greater reduction in PASI versus control (MD −2.5, 95% CI −3.8 to −1.1)... Weight-loss interventions had a significant effect on the likelihood of achieving PASI 75 (RR 1.6, 95% CI 1.1–2.2)." — Morrow S, Hawkins P, Griffiths CEM, et al. Journal of the European Academy of Dermatology and Venereology. 2025. DOI: 10.1111/jdv.70247

That establishes the baseline any GLP-1 drug has to beat. If semaglutide clears skin only as well as an equivalent amount of diet-driven weight loss, it is a convenient delivery mechanism for a known effect rather than a new one.

The second mechanism is direct immunomodulation. GLP-1 receptors are expressed on immune cells, including the invariant natural killer T cells that populate psoriatic skin. Activating those receptors appears to dampen IL-17 and IL-23 signaling — the exact axis that modern biologics like secukinumab and risankizumab target.

Evidence: "GLP-1 receptor agonists produce systemic effects, including weight loss and improved glycemic control, and local immunomodulation, such as regulating immune cells and activating metabolic pathways in affected skin areas." — Atiquzzaman N, Razdolsky N, Parmar MS. European Journal of Clinical Pharmacology. 2025. DOI: 10.1007/s00228-025-03898-4

Distinguishing the two mechanisms is the central methodological problem in this field, and no trial has cleanly solved it.

What the Randomized Trials Show

The RCT evidence is real but small. Two trials carry most of the weight.

Liraglutide

A 12-week randomized controlled trial enrolled 25 patients with psoriasis and type 2 diabetes, assigning 12 to liraglutide 1.8 mg daily and 13 to conventional therapy. Beyond the clinical scores, the investigators took skin biopsies — which is what makes this study disproportionately important for its size.

The liraglutide group showed significantly greater improvement in both PASI and Dermatology Life Quality Index, with mean DLQI falling from 22.00 ± 5.85 to 3.82 ± 3.60. Biopsies confirmed reduced expression of IL-17, IL-23, and TNF-α in lesional skin, alongside improved histopathology. No serious adverse events occurred.

Evidence: "The pathological changes of psoriasis skin and the expression of IL-17, IL-23, TNF-α in the psoriasis skin were improved in the treatment group." — Lin L, Xu X, Yu Y, et al. Journal of Dermatological Treatment. 2022. DOI: 10.1080/09546634.2020.1826392

Tissue-level cytokine suppression is the strongest available hint that something beyond weight loss is happening. A drug working purely through fat mass would not be expected to reshape the local cytokine profile this directly over 12 weeks.

Semaglutide

An open-label randomized trial in 31 patients with psoriasis, obesity, and type 2 diabetes on stable metformin assigned 15 to semaglutide 1 mg weekly and 16 to control for 12 weeks. Results favored semaglutide across serum IL-6, C-reactive protein, BMI, LDL cholesterol, and quality of life, with median DLQI dropping from 14 to 4.

Evidence: "The use of semaglutide led to a significant decrease in pro-inflammatory cytokines in the serum (IL-6), as well as a significant decrease in CRP values (p < 0.05)." — Petković-Dabić J, Binić I, Carić B, et al. Biomolecules. 2025. DOI: 10.3390/biom15010046

Putting the Trials in Context

Trial	Design	n	Drug	Duration	Key result
Lin 2022	RCT, T2DM	25	Liraglutide 1.8 mg/day	12 wk	PASI + DLQI improved; skin IL-17/IL-23/TNF-α down
Petković-Dabić 2025	Open-label RCT, T2DM + obesity	31	Semaglutide 1 mg/wk	12 wk	DLQI 14 → 4; IL-6, CRP, BMI, LDL down
Pooled prospective cohorts	Observational	23	Mixed GLP-1 RAs	3–12 mo	Median PASI −1.8

Every one of these enrolled patients with diabetes. Both RCTs ran 12 weeks. Combined, they total 56 randomized participants — roughly what a single biologic trial enrolls in its first week of recruitment. A narrative review synthesizing 14 studies found the picture genuinely mixed, including a trial showing no benefit in glucose-tolerant patients after 8 weeks.

Evidence: "Randomized controlled trials showed mixed results — one demonstrated superiority of liraglutide over controls; another found no significant difference in glucose-tolerant patients after 8 weeks." — Haran K, Johnson CE, Smith P, et al. Psoriasis: Targets and Therapy. 2024. DOI: 10.2147/PTT.S485061

That null result in metabolically healthy patients is the single most clarifying data point available. It suggests the benefit tracks the metabolic dysfunction, not the psoriasis itself.

How Much Improvement, and For Whom

The NPF primer pulled together the studies with adequately sized cohorts and landed on a headline figure: PASI reduced by roughly 50%.

That number needs framing. A 50% PASI reduction — PASI 50 — was the standard endpoint of the 1990s. Modern IL-23 inhibitors routinely deliver PASI 90 or PASI 100, meaning near-total clearance. A GLP-1 medication is not competing with risankizumab, and nobody in the NPF statement suggests otherwise. The word in the guidance is adjunctive.

The response gradient is the more actionable finding. Biologic-naïve patients with obesity appear to gain the most, while patients already established on IL-17 or IL-23 inhibitors see only modest additional benefit. That pattern is exactly what a predominantly weight-loss-mediated mechanism would predict: if the IL-23 axis is already blocked pharmacologically, removing inflammatory adipose tissue has less left to contribute.

The population-level data point the same way. A retrospective cohort using the All of Us database examined 73,225 patients with type 2 diabetes, of whom 1,601 had psoriasis and 19.6% had GLP-1 receptor agonist exposure.

Evidence: "GLP-1RA use was associated with decreased odds of psoriasis (adjusted OR 0.41; 95% CI, 0.35–0.48; P < .001) and hidradenitis suppurativa (adjusted OR 0.61; 95% CI, 0.48–0.76; P < .001)." — Ching LM, Guirguis CA, Iskandar NL, Tung JK. JAAD International. 2025. DOI: 10.1016/j.jdin.2025.07.003

A 59% lower odds of a psoriasis diagnosis is a striking figure, and it deserves a striking caveat. This is retrospective and observational. Even with adjustment for BMI, HbA1c, smoking, and diabetes medications, people prescribed GLP-1 drugs differ systematically from those who are not — in access to care, in engagement with treatment, in how often they see a clinician who might code a diagnosis. Association is not causation, and a database cannot tell you whether the drug prevented psoriasis or whether the kind of patient who gets the drug was already less likely to develop it.

Practical Considerations

For a patient with psoriasis weighing this option, several things follow from the evidence rather than from enthusiasm.

This is an add-on, not a replacement. Nobody should stop a biologic to start semaglutide. The NPF framed GLP-1 drugs as adjunctive for a reason — the effect size does not approach what targeted immunotherapy delivers.

The metabolic profile determines candidacy. Every positive trial enrolled patients with diabetes or obesity. The 8-week null result in glucose-tolerant patients is a genuine signal. A lean patient with psoriasis and no metabolic disease has no evidence base to stand on here.

Timeline is 12 weeks minimum. Both RCTs measured at 12 weeks, which roughly matches how long meaningful weight loss takes to accumulate. Skin improvement lagging behind the first weeks of treatment is expected, not a treatment failure.

Cardiometabolic benefit arrives regardless. Psoriasis independently raises cardiovascular risk, and GLP-1 drugs cut major adverse cardiac events in their own right. Even if the skin barely responds, a patient with psoriasis and obesity is getting documented cardiovascular and metabolic protection — a point our overview of GLP-1 medications and cardiovascular benefits covers in depth.

Safety looks unremarkable. No serious adverse events in either RCT. The side-effect profile is the familiar gastrointestinal one covered in our guide to GLP-1 side effects, not a dermatology-specific concern.

The unanswered question is durability. Both trials ran 12 weeks, and discontinuation of GLP-1 drugs reliably produces weight regain. If the benefit is weight-mediated, plaques would be expected to return alongside the weight. No study has followed these patients through a stop-and-regain cycle, which is precisely the scenario most likely to occur in practice.

Key Takeaways

The NPF now supports consideration of GLP-1 drugs as adjunctive therapy for psoriasis with comorbid metabolic disease, per the April 2026 JAMA Dermatology primer.
Expect roughly 50% PASI reduction in adequately sized cohorts — meaningful, but well short of what IL-17 and IL-23 inhibitors achieve.
The randomized evidence totals 56 patients across two 12-week trials, both in people with type 2 diabetes. This is a thin base for a strong claim.
Biologic-naïve patients with obesity benefit most; those already on IL-17 or IL-23 inhibitors see modest additive effect.
Mechanism remains unresolved. Skin biopsies showing reduced IL-17, IL-23, and TNF-α suggest direct immunomodulation, but a null result in metabolically healthy patients points back toward weight loss as the primary driver.
Observational data are encouraging but confounded — a 59% lower odds of psoriasis diagnosis in 73,225 diabetic patients cannot establish causation.

The honest summary is that GLP-1 medications are a reasonable addition for a specific patient: psoriasis plus obesity or diabetes, already on or considering standard therapy, who would benefit from the cardiometabolic effects whatever the skin does. That is a narrower recommendation than the headlines suggest, and it is the one the evidence actually supports.

References

Sheth S, Merola JF, Weber BN, et al. The National Psoriasis Foundation primer on GLP-1 receptor agonists in psoriasis: a review. JAMA Dermatology. 2026. DOI: 10.1001/jamadermatol.2026.0859
Lin L, Xu X, Yu Y, et al. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial. Journal of Dermatological Treatment. 2022;33(3):1428–1434. DOI: 10.1080/09546634.2020.1826392 PubMed
Petković-Dabić J, Binić I, Carić B, et al. Effects of semaglutide treatment on psoriatic lesions in obese patients with type 2 diabetes mellitus: an open-label, randomized clinical trial. Biomolecules. 2025;15(1):46. DOI: 10.3390/biom15010046 PubMed
Morrow S, Hawkins P, Griffiths CEM, et al. Impact of weight-loss interventions on psoriasis severity: a systematic review and meta-analysis. Journal of the European Academy of Dermatology and Venereology. 2025. DOI: 10.1111/jdv.70247 PubMed
Ching LM, Guirguis CA, Iskandar NL, Tung JK. Decreased incidence of hidradenitis suppurativa and psoriasis in diabetic patients treated with GLP-1 receptor agonists: a retrospective cohort study. JAAD International. 2025;22. DOI: 10.1016/j.jdin.2025.07.003 PubMed
Haran K, Johnson CE, Smith P, et al. Impact of GLP-1 receptor agonists on psoriasis and cardiovascular comorbidities: a narrative review. Psoriasis: Targets and Therapy. 2024;14. DOI: 10.2147/PTT.S485061 PubMed
Atiquzzaman N, Razdolsky N, Parmar MS. GLP-1 receptor agonists: emerging therapeutic potential in psoriasis management — current evidence and future outlook. European Journal of Clinical Pharmacology. 2025;81(11):1569–1581. DOI: 10.1007/s00228-025-03898-4 PubMed

Last updated: 2026-07-16 Medical review: Dr. James Chen, MD, PhD, FACE